- Home
- DXR vs ATNM Comparison
DXR vs ATNM Comparison
Compare DXR & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- ATNM
- Stock Information
- Founded
- DXR 1970
- ATNM 2000
- Country
- DXR United States
- ATNM United States
- Employees
- DXR N/A
- ATNM N/A
- Industry
- DXR Medical/Dental Instruments
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- ATNM Health Care
- Exchange
- DXR Nasdaq
- ATNM Nasdaq
- Market Cap
- DXR 46.9M
- ATNM 50.2M
- IPO Year
- DXR N/A
- ATNM N/A
- Fundamental
- Price
- DXR $13.00
- ATNM $1.46
- Analyst Decision
- DXR Strong Buy
- ATNM Strong Buy
- Analyst Count
- DXR 1
- ATNM 2
- Target Price
- DXR $25.00
- ATNM $4.50
- AVG Volume (30 Days)
- DXR 6.1K
- ATNM 156.2K
- Earning Date
- DXR 01-01-0001
- ATNM 11-13-2025
- Dividend Yield
- DXR N/A
- ATNM N/A
- EPS Growth
- DXR 3.46
- ATNM N/A
- EPS
- DXR 0.36
- ATNM N/A
- Revenue
- DXR $66,306.00
- ATNM N/A
- Revenue This Year
- DXR N/A
- ATNM N/A
- Revenue Next Year
- DXR N/A
- ATNM N/A
- P/E Ratio
- DXR $35.22
- ATNM N/A
- Revenue Growth
- DXR N/A
- ATNM N/A
- 52 Week Low
- DXR $6.55
- ATNM $1.03
- 52 Week High
- DXR $14.00
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- DXR 57.62
- ATNM 37.60
- Support Level
- DXR $12.70
- ATNM $1.47
- Resistance Level
- DXR $14.00
- ATNM $1.59
- Average True Range (ATR)
- DXR 0.52
- ATNM 0.08
- MACD
- DXR -0.13
- ATNM -0.01
- Stochastic Oscillator
- DXR 50.00
- ATNM 0.00
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.